智通财经APP讯,联邦制药(03933)发布公告,于2025年10月,受托人已透过市场交易购入350万股奖励股份,每股平均价格为12.905港元,以履行于2025年11月13日对已完成2024年绩效目标的承受人的归属义务。
受托人将视乎市况继续于市场购买相关数目的奖励股份,并以信托形式为相关承授人持有有关奖励股份,直至奖励股份根据股份奖励计划的条款归属予有关承授人并交收为止。
智通财经APP讯,联邦制药(03933)发布公告,于2025年10月,受托人已透过市场交易购入350万股奖励股份,每股平均价格为12.905港元,以履行于2025年11月13日对已完成2024年绩效目标的承受人的归属义务。
受托人将视乎市况继续于市场购买相关数目的奖励股份,并以信托形式为相关承授人持有有关奖励股份,直至奖励股份根据股份奖励计划的条款归属予有关承授人并交收为止。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.